Naturally occurring cutaneous anthrax: Antibiotic treatment and outcome

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 34-43

  Kayabas, U ^a   Karahocagil, M K ^b   Ozkurt, Z ^c   Metan, G ^d   Parlak, E ^c   Bayindir, Y ^a   Kalkan, A ^e   Akdeniz, H ^b   Parlak, M ^c   Simpson, A J H ^f,g   Doganay, M ^d  

^a INONU UNIVERSITY   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

^c ATATURK UNIVERSITY   (Turkey)

^d ERCIYES UNIVERSITY   (Turkey)

^e FIRAT UNIVERSITY   (Turkey)

^f DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anthrax; Antimicrobial therapy; Bacillus anthracis; Bacterial infection; Cutaneous anthrax; Gram positive bacteria

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; DOXYCYCLINE; PENICILLIN G; PREDNISOLONE; PROCAINE PENICILLIN;

ADOLESCENT; ADULT; ANTHRAX; ANTIBIOTIC THERAPY; ARTICLE; CUTANEOUS ANTHRAX; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; FEMALE; FEVER; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SHORT COURSE THERAPY; STEROID THERAPY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; WOUND HEALING;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTHRAX; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DOXYCYCLINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PENICILLIN G PROCAINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856878949     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000335593     Document Type: Article

References (40)

1. Brook I: The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002; 20: 320-325.
2. Bouzianas DG: Current and future medical approaches to combat the anthrax threat. J Med Chem 2010; 53: 4305-4331.
3. Ozcan H, Kayabas U, Bayindir Y, Bayraktar MR, Ay S: Evaluation of 23 cutaneous anthrax patients in eastern Anatolia, Turkey: Diagnosis and risk factors. Int J Dermatol 2008; 47: 1033-1037.
4. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K: Anthrax as a biological weapon, 2002: Updated recommendations for management. JAMA 2002; 287: 2236-2252.
5. Kaya A, Tasyaran MA, Erol S, Ozkurt Z, Ozkan B: Anthrax in adults and children: A review of 132 cases in Turkey. Eur J Clin Microbiol Infect Dis 2002; 21: 258-261.
6. Doganay M: Anthrax; in Cohen J, Opal SM, Powderly WG (eds): Infectious Diseases, ed 3. Amsterdam, Elsevier, 2010, pp 1257-1261.
7. Doganay M, Metan G: Human anthrax in Turkey from 1990 to 2007. Vector Borne Zoonotic Dis 2009; 9: 131-140.
8. Ronaghy HA, Azadeh B, Kohout E, Dutz W: Penicillin therapy of human cutaneous anthrax. Curr Ther Res Clin Exp 1972; 14: 721-725.
9. Doganay M, Metan G, Alp E: A review of cutaneous anthrax and its outcome. J Infect Public Health 2010; 3: 98-105.
10. Gold H: Anthrax: A report of one hundred seventeen cases. Arch Intern Med 1955; 96: 387-396.
11. Kobuch WE, Davis J, Fleischer K, Isaacson M, Turnbull PCB: A clinical and epidemiological study of 621 patients with anthrax in western Zimbabwe. Proceedings of the international workshop on anthrax. Salisbury Med Bull 1990; 68(suppl):34-38.
12. World Health Organization, Food and Agriculture Organization of the United Nations and World Organisation for Animal Health. Anthrax in Humans and Animals, ed 4. Available from: Http://www.who.int/csr/resources/ publications/anthrax-webs.pdf
13. Ellingson HV, Bookwalter HL, Howe C: Cutaneous anthrax; report of twenty-five cases. JAMA 1946; 131: 1105-1108.
14. Akbayram S, Dogan M, Akgün C, Peker E, Bektas MS, Kaya A, Caksen H, Oner AF: Clinical findings in children with cutaneous anthrax in eastern Turkey. Pediatr Dermatol 2010; 27: 600-606.
15. Karahocagil MK, Akdeniz N, Akdeniz H, Calka O, Karsen H, Bilici A, Bilgili SG, Evirgen O: Cutaneous anthrax in Eastern Turkey: A review of 85 cases. Clin Exp Dermatol 2008; 33: 406-411.
16. Maguiña C, Flores Del Pozo J, Terashima A, Gotuzzo E, Guerra H, Vidal JE, Legua P, Solari L: Cutaneous anthrax in Lima, Peru: Retrospective analysis of 71 cases, including four with a meningoencephalic complication. Rev Inst Med Trop Sao Paulo 2005; 47: 25-30.
17. Dixon TC, Meselson M, Guillemin J, Hanna PC: Anthrax. N Engl J Med 1999; 341: 815-826.
18. Seifert H, Dowzicky MJ. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007). Chemotherapy 2009; 55: 241-252.
19. Esel D, Doganay M, Sumerkan B: Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey. Int J Antimicrob Agents 2003; 22: 70-72.
20. Swartz MN: Recognition and management of anthrax -an update. N Engl J Med 2001; 345: 1621-1626.
21. Cavallo JD, Ramisse F, Girardet M, Vaissaire J, Mock M, Hernandez E: Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002; 46: 2307-2309.
22. Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, Peruski LF Jr.: MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42: 3626-3634.
23. Lightfoot NF, Scott RJD, Turnbull PC: Antimicrobial susceptibility of Bacillus anthracis Salisbury Med Bull 1990; 68(spec suppl):95-98.
24. Mohammed MJ, Marston CK, Popovic T, Weyant RS, Tenover FC: Antimicrobial susceptibility testing of Bacillus anthracis : Comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002; 40: 1902-1907.
25. Coker PR, Smith KL, Hugh-Jones ME: Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002; 46: 3843-3845.
26. Maho A, Rossano A, Hächler H, Holzer A, Schelling E, Zinsstag J, Hassane MH, Toguebaye BS, Akakpo AJ, Van Ert M, Keim P, Kenefic L, Frey J, Perreten V: Antibiotic susceptibility and molecular diversity of Bacillus anthracis strains in Chad: Detection of a new phylogenetic subgroup. J Clin Microbiol 2006; 44: 3422-3425.
27. Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J: Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60: 555-567.
28. Metan G, Doganay M: The antimicrobial susceptibility of Bacillus anthracis isolated from human cases: A review of the Turkish literature. Turkiye Klinikleri J Med Sci 2009; 29: 229-235.
29. Oncul O, Ozsoy MF, Gul HC, Koçak N, Cavuslu S, Pahsa A: Cutaneous anthrax in Turkey: A review of 32 cases. Scand J Infect Dis 2002; 34: 413-416.
30. Doganay M, Aydin N: Antimicrobial susceptibility of Bacillus anthracis Scand J Infect Dis 1991; 23: 333-335.
31. Bakici MZ, Elaldi N, Bakir M, Dökmetas I, Erandaç M, Turan M: Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34: 564-566.
32. Demirdag K, Ozden M, Saral Y, Kalkan A, Kilic SS, Ozdarendeli A: Cutaneous anthrax in adults: A review of 25 cases in the eastern Anatolian region of Turkey. Infection 2003; 31: 327-330.
33. Martin GJ, Friedlander AM: Bacillus anthracis (Anthrax); in Mandell GL, Bennett JE, Dolin R (eds): Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, ed 7. Philadelphia, Churchill Livingstone, 2010, pp 2715-2725.
34. Stern EJ, Uhde KB, Shadomy SV, Messonnier N: Conference report on public health and clinical guidelines for anthrax (conference summary). Emerg Infect Dis (serial on the Internet). 2008 Apr, cited 24 January 2011. Available from http://www.cdc.gov/EID/ content/14/4/07-0969.htm.
35. Bryskier A: Bacillus anthracis and antibacterial agents. Clin Microbiol Infect 2002; 8: 467-478.
36. Vietri NJ, Purcell BK, Tobery SA, Rasmussen SL, Leffel EK, Twenhafel NA, Ivins BE, Kellogg MD, Webster WM, Wright ME, Friedlander AM: A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis 2009; 199: 336-341.
37. Allerberger F, Lechner A, Wechsler-Fördös A, Gareis R: Optimization of antibiotic use in hospitals-antimicrobial stewardship and the EU project ABS international. Chemotherapy 2008; 54: 260-267.
38. Kurt H, Karabay O, Birengel S, Memikoglu O, Yilmaz Bozkurt G, Yalçi A: Effects of legal antibiotic restrictions on consumption of broad-spectrum-lactam antibiotics, glycopeptides and amphotericin B. Chemotherapy 2010; 56: 359-363.
39. Lincoln RE, Klein F, Walker JS, Haines BW, Jones WI, Mahlandt BG, Friedman RH: Successful treatment of rhesus monkeys for septicemic anthrax. Antimicrob Agents Chemother 1964; 10: 759-763.
40. Doust JY, Sarkarzadeh A, Kavoossi K: Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968; 53: 773-774.